New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2013
07:10 EDTPCYCPharmacyclics could beat 2014-2015 consensus estimates, says RBC Capital
RBC Capital expects the launch of Pharmacyclics' Imbruvica to exceed expectations, and the firm raised its price target on the shares to $150 from $125. It keeps an Outperform rating on the stock.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use